Nitroglycerin lingual spray - Mist Pharmaceuticals

Drug Profile

Nitroglycerin lingual spray - Mist Pharmaceuticals

Alternative Names: NitroMist

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator NovaDel Pharma
  • Developer Mist Pharmaceuticals
  • Class Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Angina pectoris

Most Recent Events

  • 19 Nov 2013 Mist Pharmaceuticals acquires all patents, trademarks and license agreements related to nitroglycerin lingual spray
  • 16 Jul 2013 Biomarkers information updated
  • 08 Apr 2013 Nitroglycerin lingual spray - NovaDel Pharma is available for purchase as of 08 Apr 2013. http://www.novadel.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top